Search

Zai Lab Ltd ADR

Lezárt

SzektorEgészségügy

24.08 0.21

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

23.99

Maximum

24.22

Fő mutatók

By Trading Economics

Bevétel

191K

-51M

Értékesítés

6.7M

106M

Egy részvényre jutó nyereség

-0.46

Profit margin

-47.808

Munkavállalók

1,784

EBITDA

-2.1M

-46M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+62.94% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

892M

2.9B

Előző nyitás

23.87

Előző zárás

24.08

Hangulat hírek alapján

By Acuity

38%

62%

94 / 339 Rangsor szerint Healthcare

Zai Lab Ltd ADR Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 11. 23:56 UTC

News

Ionis Pharmaceuticals received FDA approval for ZANVASTRO. Shares are higher in after-market trading, reflecting positive sentiment despite a setback in a partnered trial.

2026. szept. 11. 23:41 UTC

News
Social Media

Johnson & Johnson shares higher after news of Apollo Global Management's interest in acquiring its $20 billion orthopedics unit, DePuy Synthes.

2026. szept. 11. 23:26 UTC

News

Bentley Systems declared a quarterly dividend of $0.07 per share, scheduled for September 29, 2026, with shares trading higher in after-market hours.

2026. szept. 11. 23:16 UTC

News

Carriage Services Inc shares higher in after-hours trading, following a Friday close. Analysts set an average price target of $51.00, indicating potential upside.

2026. szept. 11. 23:06 UTC

Macro Event
News

Ethereum is higher in Friday's session, recovering after four days of declines. The asset remains above its 20-day moving average amid rising inflation pressures.

2026. szept. 11. 23:06 UTC

Macro Event
News

Ethereum is rising during Friday's session, supported by recent inflation data and fluctuating crude oil prices. The asset remains above its 20-day moving average.

2026. szept. 11. 23:01 UTC

Social Media
News

Oracle Corp's after-market shares declined following a $700 million expansion of its restructuring plan, raising total costs to $2.8 billion amid financial pressures.

2026. szept. 11. 23:01 UTC

News

Nasdaq Inc. shares rose in after-market trading following a $100 million investment in Payward to develop Nasdaq Equity Tokens, set to launch in 2027.

2026. szept. 11. 23:01 UTC

Social Media
News

Corning Inc shares fell in after-market trading following a $2 billion stock offering announcement, raising investor concerns about potential dilution.

2026. szept. 11. 22:51 UTC

News
Social Media

Scholar Rock Holding Corp gains after FDA approves ISEMBYLD for spinal muscular atrophy, with a U.S. launch set to begin shortly.

2026. szept. 11. 22:01 UTC

News

Estée Lauder Companies secured a legal win against Walmart over counterfeit products, but shares are trading lower in after-market hours amid ongoing retail sector concerns.

2026. szept. 11. 21:31 UTC

News

Warner Bros Discovery Inc. shares are higher in after-market hours following reports of Paramount's settlement talks with state attorneys general over its acquisition proposal.

2026. szept. 11. 20:51 UTC

News

Ralph Lauren Corp's Board declared a quarterly dividend of $1.00 per share, and shares are trading higher in after-market hours.

2026. szept. 11. 20:09 UTC

News

1-800-Flowers.Com Inc shares are lower after reporting Q2 revenue of $293.1 million and a non-GAAP loss of $0.80 per share.

2026. szept. 11. 20:09 UTC

News

Century Communities plans to open Grand Oaks of Callaway in Florida on September 26, featuring homes starting from the upper $200s. Shares are gaining.

2026. szept. 11. 20:09 UTC

News

Columbia Sportswear appoints Peter Rauch as President of Mountain Hardwear, effective September 28. Shares are higher today, despite pulling back from an earlier session high.

2026. szept. 11. 20:09 UTC

News

Clear Secure shares are lower after DA Davidson analyst Wyatt Swanson cut the price target to $45.00 from $55.00 while maintaining a Neutral rating.

2026. szept. 11. 20:09 UTC

News

Carvana Co's shares are lower today, continuing a downward trend amid institutional investment activity and persistent inflation pressures indicated by recent CPI data.

2026. szept. 11. 20:09 UTC

News

Ultragenyx Pharmaceutical shares are lower as Bronstein, Gewirtz & Grossman, LLC, initiates an investigation following disappointing Phase 3 study results for apazunersen.

2026. szept. 11. 20:09 UTC

News
Social Media
Correlated Moves

Snowflake Inc. shares are declining amid insider selling by director Benoit Dageville, who sold 50,000 shares at $335.72 on September 9.

2026. szept. 11. 20:09 UTC

News
Social Media

Advanced Micro Devices shares are higher today following positive growth projections for its server and data center businesses, potentially exceeding $65 billion by Q4 2026.

2026. szept. 11. 20:09 UTC

News

Intercontinental Exchange sponsors the 9/11 Day of Service initiative. Shares are advancing during Friday's trading, reflecting positive momentum since Thursday's close.

2026. szept. 11. 20:09 UTC

News
Social Media

Marvell Technology reports fiscal Q2 revenue of $2.73 billion, exceeding estimates. Shares are higher amid strong demand for AI networking and advanced technologies.

2026. szept. 11. 20:09 UTC

News

D.R. Horton shares advance despite Wells Fargo lowering the price target to $145, amid concerns over declining demand in the homebuilding sector.

2026. szept. 11. 20:09 UTC

Correlated Moves
News

Citigroup shares reached an eight-week high earlier today, reflecting positive investor sentiment. The stock remains higher since Thursday, supported by the S&P 500's advance.

2026. szept. 11. 20:09 UTC

News
Social Media
Macro Event

Intel shares are higher today, bolstered by a Northland upgrade to Outperform and significant wafer processing milestones using ASML's High-NA EUV machines.

2026. szept. 11. 20:09 UTC

Correlated Moves
Social Media
News

Coinbase shares are higher as CFO Alesia Haas outlines contingency plans for regulatory clarity amid rising Ethereum prices.

2026. szept. 11. 20:09 UTC

Social Media
News

DA Davidson upgraded Palantir Technologies to Buy and raised its price target to $250, citing strong AI focus and positive market sentiment. Shares have gained since Thursday.

2026. szept. 11. 20:09 UTC

News
Macro Event

Paysign shares are lower amid negative sentiment from insider selling and broader market pressures, including a decline in the Michigan Consumer Sentiment index.

2026. szept. 11. 20:09 UTC

News

Visa has launched an onchain lending initiative with Credit Coop, financing $2.5 billion to address funding gaps from daily card settlements. Shares are higher today.

Társak összehasonlítása

Árváltozás

Zai Lab Ltd ADR Előrejelzés

Célár

By TipRanks

62.94% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 39.333 USD  62.94%

Magas 45 USD

Alacsony 36 USD

3 Wall Street elemző 12 hónapos célárain alapulva a(z)Zai Lab Ltd ADR termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

3 ratings

3

Vétel

0

Tartás

0

Eladás

Hangulat

By Acuity

94 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat